REG-4basebio Plc: Exercise of Options

4BasebioAnnouncement

Today 07:02

25 June 2025

   
     

4basebio PLC

("4basebio" or the "Company")

Exercise of Options

Cambridge, UK, 25 June 2025 – 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform, announces that, on 19 June 2025, it received
notification from two employees of the Company to exercise EMI options over
13,000 ordinary shares (“New Ordinary Shares”) in the Company at an
exercise price of £1.18 per share, raising total proceeds of £15,340.

Admission to AIM

Application will be made for the New Ordinary Shares to be admitted to trading
on AIM ("Admission"). It is expected that Admission will become effective at
8:00 a.m. on or around 30 June 2025. The New Ordinary Shares will be issued
credited as fully paid and will rank in full for all dividends and other
distributions declared, made or paid after Admission and will otherwise rank
on Admission pari passu in all respects with the existing ordinary shares.

Total Voting Rights

Following Admission, the total number of ordinary shares in issue will be
15,509,393. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares with voting rights will be
15,509,393. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC Dr. Heikki Lanckriet, CEO                                                              +44 (0)1223 967 943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson / Ed Downes         +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes                                    +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                             +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved